Pomalidomide 2 MG Oral Capsule — RxCUI 1369726
RxNorm drug concept · Semantic clinical drug
RxCUI 1369726
Semantic clinical drug · SCD
● Current RxNorm concept 28 FDA products
48 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1369726
Official namePomalidomide 2 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped28
Package NDCs mapped48
Reported Medicaid activity (SDUD)2,329 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Pomalidomide: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats multiple myeloma, taken with dexamethasone after at least two earlier treatments. It also treats Kaposi sarcoma, either AIDS-related after HIV therapy has failed or in pe...
- You take one capsule by mouth once a day, with or without food, for Days 1 through 21 of each 28-day cycle. Follow your prescriber's schedule exactly. Your dose may change dependin...
- It is never safe during pregnancy because it can cause severe birth defects. Women who can become pregnant need pregnancy tests and two forms of birth control. Men must use a condo...
- Is it safe if I could become pregnant, or if my partner could?
🕸️ Concept Web — How Pomalidomide 2 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Pomalidomide 2 MG Oral Capsule
RxCUI 1369726 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Pomalidomide
1369713IN
-
Pomalidomide
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Pomalyst
1369719BN
-
Pomalyst
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Pomalidomide Oral Capsule
1369717SCDF -
Pomalidomide Oral Product
1369715SCDG -
Pomalidomide Pill
1369716SCDG -
Pomalidomide Oral Capsule [Pomalyst]
1369721SBDF -
Pomalyst Oral Product
1369722SBDG -
Pomalyst Pill
1369723SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Pomalidomide Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Pomalidomide 2 MG
1369725SCDC -
Pomalidomide 2 MG Oral Capsule [Pomalyst]
1369728SBD -
Pomalidomide 2 MG [Pomalyst]
1369727SBDC
-
Pomalidomide 2 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Pomalidomide 2 MG
SCDC · 1369725 -
Pomalidomide Oral Capsule
SCDF · 1369717 -
Pomalidomide Oral Product
SCDG · 1369715 -
Pomalidomide Pill
SCDG · 1369716
Brand-Name Concepts
-
Pomalidomide 2 MG Oral Capsule [Pomalyst]
SBD · 1369728 -
Pomalidomide 2 MG [Pomalyst]
SBDC · 1369727 -
Pomalidomide Oral Capsule [Pomalyst]
SBDF · 1369721 -
Pomalyst Oral Product
SBDG · 1369722 -
Pomalyst Pill
SBDG · 1369723 -
Pomalyst
BN · 1369719
📦 FDA Products & Package NDCs
28 products · 48 package NDCs
48 package NDCs map to RxCUI 1369726 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00480-2601-21 | 21 CAPSULE in 1 BOTTLE (0480-2601-21) | Pomalidomide | Teva Pharmaceuticals, Inc. | 2026-03-02 |
| 00480-4018-21 | 21 CAPSULE in 1 BOTTLE (0480-4018-21) | Pomalidomide | Teva Pharmaceuticals, Inc. | 2026-03-02 |
| 00480-4022-21 | 21 CAPSULE in 1 BOTTLE (0480-4022-21) | Pomalidomide | Teva Pharmaceuticals, Inc. | 2026-03-02 |
| 00480-4035-21 | 21 CAPSULE in 1 BOTTLE (0480-4035-21) | Pomalidomide | Teva Pharmaceuticals, Inc. | 2026-03-02 |
| 31722-0770-01 | 100 CAPSULE in 1 BOTTLE (31722-770-01) | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0770-21 | 21 CAPSULE in 1 BOTTLE (31722-770-21) | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0770-32 | 6 BLISTER PACK in 1 CARTON (31722-770-32) / 10 CAPSULE in 1... | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0771-01 | 100 CAPSULE in 1 BOTTLE (31722-771-01) | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0771-21 | 21 CAPSULE in 1 BOTTLE (31722-771-21) | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0771-32 | 6 BLISTER PACK in 1 CARTON (31722-771-32) / 10 CAPSULE in 1... | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0772-01 | 100 CAPSULE in 1 BOTTLE (31722-772-01) | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0772-21 | 21 CAPSULE in 1 BOTTLE (31722-772-21) | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0772-32 | 6 BLISTER PACK in 1 CARTON (31722-772-32) / 10 CAPSULE in 1... | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0773-01 | 100 CAPSULE in 1 BOTTLE (31722-773-01) | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0773-21 | 21 CAPSULE in 1 BOTTLE (31722-773-21) | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 31722-0773-32 | 6 BLISTER PACK in 1 CARTON (31722-773-32) / 10 CAPSULE in 1... | Pomalidomide | Camber Pharmaceuticals, Inc. | 2026-02-28 |
| 51991-0342-21 | 21 CAPSULE in 1 BOTTLE, PLASTIC (51991-342-21) | Pomalidomide | Breckenridge Pharmaceutical, Inc. | 2026-02-28 |
| 51991-0343-21 | 21 CAPSULE in 1 BOTTLE, PLASTIC (51991-343-21) | Pomalidomide | Breckenridge Pharmaceutical, Inc. | 2026-02-28 |
| 51991-0344-21 | 21 CAPSULE in 1 BOTTLE, PLASTIC (51991-344-21) | Pomalidomide | Breckenridge Pharmaceutical, Inc. | 2026-02-28 |
| 51991-0346-21 | 21 CAPSULE in 1 BOTTLE, PLASTIC (51991-346-21) | Pomalidomide | Breckenridge Pharmaceutical, Inc. | 2026-02-28 |
| 59572-0501-00 | 100 CAPSULE in 1 BOTTLE (59572-501-00) | Pomalyst | Celgene Corporation | 2013-02-18 |
| 59572-0501-21 | 21 CAPSULE in 1 BOTTLE (59572-501-21) | Pomalyst | Celgene Corporation | 2013-02-18 |
| 59572-0502-00 | 100 CAPSULE in 1 BOTTLE (59572-502-00) | Pomalyst | Celgene Corporation | 2013-02-18 |
| 59572-0502-21 | 21 CAPSULE in 1 BOTTLE (59572-502-21) | Pomalyst | Celgene Corporation | 2013-02-18 |
| 59572-0503-00 | 100 CAPSULE in 1 BOTTLE (59572-503-00) | Pomalyst | Celgene Corporation | 2013-02-18 |
| 59572-0503-21 | 21 CAPSULE in 1 BOTTLE (59572-503-21) | Pomalyst | Celgene Corporation | 2013-02-18 |
| 59572-0504-00 | 100 CAPSULE in 1 BOTTLE (59572-504-00) | Pomalyst | Celgene Corporation | 2013-02-18 |
| 59572-0504-21 | 21 CAPSULE in 1 BOTTLE (59572-504-21) | Pomalyst | Celgene Corporation | 2013-02-18 |
| 59651-0194-01 | 100 CAPSULE in 1 BOTTLE (59651-194-01) | Pomalidomide | Aurobindo Pharma Limited | 2020-10-30 |
| 59651-0194-21 | 21 CAPSULE in 1 BOTTLE (59651-194-21) | Pomalidomide | Aurobindo Pharma Limited | 2020-10-30 |
| 59651-0195-01 | 100 CAPSULE in 1 BOTTLE (59651-195-01) | Pomalidomide | Aurobindo Pharma Limited | 2020-10-30 |
| 59651-0195-21 | 21 CAPSULE in 1 BOTTLE (59651-195-21) | Pomalidomide | Aurobindo Pharma Limited | 2020-10-30 |
| 59651-0196-01 | 100 CAPSULE in 1 BOTTLE (59651-196-01) | Pomalidomide | Aurobindo Pharma Limited | 2020-10-30 |
| 59651-0196-21 | 21 CAPSULE in 1 BOTTLE (59651-196-21) | Pomalidomide | Aurobindo Pharma Limited | 2020-10-30 |
| 59651-0197-01 | 100 CAPSULE in 1 BOTTLE (59651-197-01) | Pomalidomide | Aurobindo Pharma Limited | 2020-10-30 |
| 59651-0197-21 | 21 CAPSULE in 1 BOTTLE (59651-197-21) | Pomalidomide | Aurobindo Pharma Limited | 2020-10-30 |
| 60505-4497-02 | 21 CAPSULE in 1 BOTTLE (60505-4497-2) | Pomalidomide | Apotex Corp. | 2026-03-11 |
| 60505-4498-02 | 21 CAPSULE in 1 BOTTLE (60505-4498-2) | Pomalidomide | Apotex Corp. | 2026-03-11 |
| 60505-4499-02 | 21 CAPSULE in 1 BOTTLE (60505-4499-2) | Pomalidomide | Apotex Corp. | 2026-03-11 |
| 60505-4500-02 | 21 CAPSULE in 1 BOTTLE (60505-4500-2) | Pomalidomide | Apotex Corp. | 2026-03-11 |
| 63850-0131-01 | 21 CAPSULE in 1 BOTTLE (63850-0131-1) | Pomalidomide | Natco Pharma Limited | 2025-11-01 |
| 63850-0131-02 | 100 CAPSULE in 1 BOTTLE (63850-0131-2) | Pomalidomide | Natco Pharma Limited | 2025-11-01 |
| 63850-0132-01 | 21 CAPSULE in 1 BOTTLE (63850-0132-1) | Pomalidomide | Natco Pharma Limited | 2025-11-01 |
| 63850-0132-02 | 100 CAPSULE in 1 BOTTLE (63850-0132-2) | Pomalidomide | Natco Pharma Limited | 2025-11-01 |
| 63850-0133-01 | 21 CAPSULE in 1 BOTTLE (63850-0133-1) | Pomalidomide | Natco Pharma Limited | 2025-11-01 |
| 63850-0133-02 | 100 CAPSULE in 1 BOTTLE (63850-0133-2) | Pomalidomide | Natco Pharma Limited | 2025-11-01 |
| 63850-0134-01 | 21 CAPSULE in 1 BOTTLE (63850-0134-1) | Pomalidomide | Natco Pharma Limited | 2025-11-01 |
| 63850-0134-02 | 100 CAPSULE in 1 BOTTLE (63850-0134-2) | Pomalidomide | Natco Pharma Limited | 2025-11-01 |
Observed labelers:
Camber Pharmaceuticals, Inc. (12) ·
Aurobindo Pharma Limited (8) ·
Celgene Corporation (8) ·
Natco Pharma Limited (8) ·
Apotex Corp. (4) ·
Breckenridge Pharmaceutical, Inc. (4)
· +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.